PubRank

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)

Clinical Trial ID NCT01171898

PubWeight™ 17.41‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01171898

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 2.01
2 Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 1.31
3 Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013 1.21
4 Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013 1.19
5 Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013 1.16
6 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
7 AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev 2014 0.91
8 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
9 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
10 Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther 2013 0.85
11 Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol 2014 0.84
12 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
13 Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2014 0.82
14 Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci 2016 0.81
15 Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol 2016 0.81
16 New drugs in prostate cancer. Prostate Int 2016 0.80
17 New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer 2011 0.79
18 Recent advances in prostate development and links to prostatic diseases. Wiley Interdiscip Rev Syst Biol Med 2013 0.79
Next 100